000			04421cam a2200445Mi 4500
001			94790
003			ES-MaUEC
005			20230102112632.0
006			m o d
007			cr cnu---unuuu
008			161105t20162017sz o 000 0 eng d
020			_a3319418254 _q(electronic bk.)
020			_a9783319418254 _q(electronic bk.)
020			_z3319418238
020			_z9783319418230 _q(print)
035			_a(OCoLC)961455789 _z(OCoLC)962009293
040			_aEBLCP _cEBLCP _dGW5XE _dN$T _dOCLCQ _dOCLCF _dYDX _dUAB _dIDEBK _dIOG _dESU _dOHI _dMERER _dJBG _dIAD _dICW _dICN _dOCLCQ _dOTZ _dOCLCQ _dU3W _dES-MaUEC _bspa
050		4	_aRC262 _b2017 EB
245	0	0	_aRe-irradiation : _bnew frontiers _cCarsten Nieder, Johannes Langendijk, editors.
250			_a2nd ed.
264		1	_aCham, Switzerland _bSpringer International Publishing
300			_a1 recurso en línea (365 páginas)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aMedical radiology
490	0		_aRadiation Oncology
505	0		_aContributors; Normal Tissue Tolerance to Reirradiation; 1 Introduction; 2 Acute Reactions; 2.1 Skin and Mucosa; 2.2 Intestine; 3 Late Side Effects; 3.1 Epithelial and Mesenchymal Tissues; 3.2 Thoracic Aorta and Carotid Arteries; 3.3 Intestine; 3.4 Lung; 3.5 Spinal Cord; 3.6 Brain; 3.7 Heart; 3.8 Bladder; 3.9 Kidney; 4 Liver; 5 Discussion; References; Fractionation Concepts; 1 Background; 2 Hyperfractionation in First--Line Radiotherapy; 3 Hyperfractionated Reirradiation; 4 Low-Dose Ultrafractionation; 5 Pulse-Reduced Dose Rate (PRDR) Reirradiation.
505	8		_a1 Introduction: Errors, Margins and Compensation Strategies in Radiotherapy1.1 Rationale for Advanced Technologies in the Reirradiation Situation; 1.2 Uncertainties in Radiotherapy and Compensation Strategies; 1.3 Safety Margins in Radiotherapy; 2 Imaging for Reirradiation; 3 Photon External Beam Radiotherapy; 3.1 Conventional Two- Dimensional Radiotherapy; 3.2 Three-Dimensional Conformal Radiotherapy; 3.3 Intensity-Modulated Radiotherapy; 4 Three and Four Dimensional Treatment Plan Evaluation; 5 Stereotactic Radiotherapy and Image Guidance; 6 Intrafractional Motion Management.
505	8		_a2 The Rationale to Integrate Hyperthermia into Multimodality Approaches for the Treatment of Recurrent Malignancies; 3 Clinical Data; 3.1 Breast Cancer; 3.2 Rectal Cancer; 3.3 Head and Neck Cancer; 3.4 Cervical Cancer; 4 Summary; References; Therapeutic Ratio of Reirradiation with Cytotoxic Drugs and Other Response-Modifying Agents; 1 Introduction; 2 Clinical Relevance of Combined Modality Approaches; 3 Basic Considerations; 3.1 Therapeutic Gain; 3.2 Additivity, Synergism, and Subadditivity; 3.2.1 Synergism (Supraadditivity); 3.2.2 Additivity.
505	8		_a3.2.3 Infra (Sub)-additivity (Protection); 4 Interaction of Radiation and Chemotherapy; 4.1 Spatial Interaction; 4.2 Role of Repopulation; 4.3 Role of Hypoxia; 5 Molecular Interactions; 5.1 DNA Damage; 5.2 Radiation Sensitization via Cell Cycle Synchronization; 6 Radiation and Platinum--Based Drugs: Example of Clinically Established Combined Modality Treatments; 6.1 Cisplatin; 6.2 Carboplatin; 6.3 Oxaliplatin; 7 Combined Modality Reirradiation; References; Reduced Normal Tissue Doses Through Advanced Technology.
505	8		_a6 Hypofractionation in Randomized Clinical Reirradiation Studies; 7 A Small Randomized Study of Conventionally Fractionated External Beam Radiotherapy Versus High--Dose--Rate (HDR) Brachytherapy; References; Hyperthermia and Reirradiation; 1 Hyperthermia in Clinical Oncology; 1.1 Classical Hyperthermia Treatment Techniques; 1.1.1 Superficial Hyperthermia; 1.1.2 Interstitial and Endocavitary/Intraluminal Hyperthermia; 1.1.3 Deep Regional Hyperthermia; 1.1.4 Noninvasive Thermometry; 1.1.5 Whole-Body Hyperthermia; 1.2 Hyperthermia: Not an Alternative but Additive Treatment Option.
505	8		_a6.1 Patient Motion Management.
650		7	_aRadioterapia _2embne _0(OCoLC)fst01088351 _0 _9139979
700	1		_aLangendijk, Johannes A.
700	1		_aNieder, C. _q(Carsten), _d1964-
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-41825-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c94790 _d94790 _x1